Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up-Reference-Cited by-同舟云学术

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up

Published:2012-09 Issue:9 Volume:23 Page:2380-2385
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Colombat P.,Brousse N.,Salles G.,Morschhauser F.,Brice P.,Soubeyran P.,Delwail V.,Deconinck E.,Haioun C.,Foussard C.,Sebban C.,Tilly H.,Thieblemont C.,Bergougnoux L.,Lazreg F.,Solal-Celigny P.

Funder

Roche, Boulogne-Billancourt

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/9/2380/13788747/mds177.pdf

Reference25 articles.

1. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte;Brice;J Clin Oncol,1997

2. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial;Ardeshna;Lancet,2003

3. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment;Young;Semin Hematol.,1988

4. Minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma;Hiddemann;Ann Oncol,2005

5. How I treat indolent lymphoma;Gribben;Blood,2007

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II Japanese trial of 90-minute rituximab infusion for untreated B-cell lymphoma;Japanese Journal of Clinical Oncology;2024-01-25

2. A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas;Lymphatics;2024-01-05

3. Treatment of follicular lymphoma with a focus on radiotherapy;The Royal College of Radiologists Open;2024

4. Non-Hodgkin lymphoma treated with anti-CD20 antibody-based immunochemotherapy;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

5. Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study;Journal of Clinical Oncology;2023-07-01